International Biotechnology Trust forms partnership with Schroders Capital

International Biotechnology Trust PLC (IBT) has formed a partnership with Schroders Capital, committing an initial £10 million, representing approximately 4% of its portfolio value, to expand its investments in unquoted biotechnology opportunities. This strategic move aims to provide IBT shareholders with diversified access to innovative earlier-stage companies through unquoted funds, aligning with the trust's long-term capital growth strategy and leveraging Schroders Capital's extensive sector expertise. The agreement includes a management fee for Schroders Capital, capped at 0.25% of IBT's net asset value annually.

Analysis

International Biotechnology Trust PLC (IBT) is strategically increasing its exposure to the private biotech sector through a new partnership with Schroders Capital, committing an initial £10 million, which represents approximately 4% of its current portfolio value. This action will raise IBT's total allocation to unquoted companies to approximately 12.4%, placing it near the top of its stated 5-15% policy range and indicating a deliberate effort to capture growth from earlier-stage, innovative firms. The partnership leverages Schroders Capital's extensive 25-year track record, which includes over $4.3 billion committed across the healthcare and biotechnology sectors, providing a layer of experienced management for this higher-risk asset class. A key feature for investors is the fee structure, which includes a management fee of 0.9% on the committed assets but is ultimately capped at 0.25% of IBT’s total net asset value, protecting overall returns from disproportionate costs. This move diversifies IBT's exposure beyond its existing unquoted holdings managed by SV Health Partners and provides shareholders with structured, diversified access to long-term growth opportunities in the private markets.

Key Decisions for Investors

• Investors with a long-term growth mandate should see this as a positive strategic enhancement, as it deepens IBT's access to the high-risk, high-reward segment of early-stage private biotechnology.
• It is prudent to monitor the performance of this new unquoted portfolio sleeve, as the successful deployment of capital by Schroders will be a critical factor for future Net Asset Value (NAV) growth.
• Consider that the increased allocation to less liquid unquoted assets, now totaling ~12.4% of the portfolio, may introduce greater NAV volatility, and investors should weigh this against the potential for higher long-term returns and the risk mitigation provided by a professional manager and a capped fee structure.